Realty Income Corp vs Twist Bioscience Corp — how do they compare? Realty Income Corp trades at $65.09 (market cap $60.60B), while Twist Bioscience Corp trades at $93.82 (market cap $5.97B). The key difference: Realty Income Corp is far larger — about 10.2× Twist Bioscience Corp's market cap, and Realty Income Corp pays a 5% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| O | TWST | |
|---|---|---|
Market Cap | $60.60B | $5.97B |
Sector | Real Estate | Health |
52-Week High | $67.56 | $102.88 |
52-Week Low | $55.93 | $24.16 |
Enterprise Value | $90.40B | $5.89B |
Dividend Yield | 5% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Trailing returns across standard periods
Latest headlines on both assets
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →